Indications for Blood Transfusion in Pregnancy

1. Antenatal (during pregnancy)

• Severe iron-deficiency/nutritional anaemia not correctable in time with iron therapy: transfusion (or high-dose parenteral iron) is indicated when haemoglobin is severely low (classically <7 g/dl, or <10 g/dl with ongoing symptoms/near term) - Park's Textbook of Preventive and Social Medicine.
• Haemoglobinopathies - sickle cell disease and thalassaemia major/intermedia. Patients may need prophylactic or top-up transfusion to prevent sickle crises, correct profound anaemia, or manage hypersplenism; some become transfusion-dependent (Bailey and Love's Short Practice of Surgery, 28th ed.). A 2024 systematic review/meta-analysis (PMID: 39252331) examined prophylactic transfusion in sickle cell pregnancies and its effect on maternal/fetal outcomes - worth checking if managing a sickle cell pregnancy, as evidence here is evolving.
• Antepartum haemorrhage from placenta praevia, placental abruption, or vasa praevia causing significant blood loss.
• Placenta accreta spectrum disorders (especially in twin pregnancies) carry a high risk of massive haemorrhage requiring transfusion at delivery, often anticipated and planned for in advance (per a 2023 meta-analysis, PMID: 34328297).

2. Intrapartum / Peripartum - Obstetric Haemorrhage

• Postpartum haemorrhage (PPH) - uterine atony, retained placenta, trauma/lacerations, coagulopathy (the "4 Ts": Tone, Tissue, Trauma, Thrombin).
• Uterine rupture.
• Placenta accreta/increta/percreta at caesarean section.
• Historically, transfusion for postpartum haemorrhage was in fact the first documented successful human blood transfusion (James Blundell, 1818) - Bailey and Love's Short Practice of Surgery.

3. Postpartum

• Correction of ongoing anaemia from delivery blood loss when symptomatic (tachycardia, hypotension, dyspnoea, evidence of poor oxygen delivery) rather than by haemoglobin number alone.
• Post-PPH management: several trials (e.g., referenced in Tietz Textbook of Laboratory Medicine) have specifically studied transfusion policy after severe postpartum haemorrhage to define restrictive vs liberal thresholds.

General principles guiding the decision to transfuse

• Symptomatic anaemia / physiological compromise takes precedence over a fixed haemoglobin trigger.
• In hypovolaemia from acute haemorrhage, restoring circulating volume is more urgent than simply raising the haematocrit (Pye's Surgical-Handicraft).
• Adjuncts used to reduce/avoid transfusion in obstetric haemorrhage include uterotonics, tranexamic acid, uterine compression sutures (B-Lynch), intrauterine balloon tamponade, interventional radiology (uterine artery embolisation), and cell salvage - all aimed at limiting the volume of blood products ultimately required.

Related evidence worth flagging

• A 2024 Cochrane review (PMID: 39651609) compared IV vs oral iron for iron-deficiency anaemia in pregnancy - relevant because effective antenatal iron correction reduces the likelihood of needing transfusion later.
• A 2024 systematic review on prophylactic transfusion in sickle cell pregnancy (PMID: 39252331) - if you're managing a sickle cell pregnancy specifically, this is worth a closer look as practice in this area continues to be refined.

Key Clinical Guidelines on Blood Transfusion in Pregnancy

1. RCOG Green-top Guideline No. 47 - Blood Transfusions in Obstetrics (UK)

• Covers appropriate use of blood products in pregnancy and the puerperium, aiming to neither withhold necessary transfusion nor expose women to unnecessary risk.
• Recommends blood group and antibody screening at booking and again at 28 weeks' gestation so cross-matched blood is readily available if needed in labour.
• Advises women at high risk of haemorrhage (e.g., placenta praevia/accreta, known bleeding disorders) to deliver in units with on-site transfusion and critical care facilities.
• Discusses strategies to maximise haemoglobin before delivery (antenatal iron correction) and to minimise blood loss, reducing the eventual need for transfusion.
• Addresses risks of transfusion itself (infection, TRALI, alloimmunisation) that must be weighed against benefit.

2. RCOG Green-top Guideline No. 52 - Prevention and Management of Postpartum Haemorrhage (2016, reaffirmed)

• Defines PPH: minor (500-1000 ml), major (>1000 ml - moderate 1000-2000 ml, severe >2000 ml). Transfusion decisions are tied to these thresholds combined with clinical signs of compromise, not blood loss volume alone.
• Recommends a multidisciplinary major obstetric haemorrhage protocol at every unit, with early activation of massive transfusion pathways (red cells, FFP, platelets, cryoprecipitate in defined ratios, guided by viscoelastic testing where available) once bleeding is significant.
• Does not cover women who decline transfusion (e.g., Jehovah's Witnesses) or those with pre-existing bleeding disorders/on anticoagulants - it directs to other specific sources for those situations.

3. ACOG Practice Bulletin No. 183 - Postpartum Hemorrhage (2017, US)

• Defines PPH as cumulative blood loss ≥1000 ml or blood loss with signs/symptoms of hypovolemia within 24 hours of birth (revised from the older 500 ml vaginal-delivery threshold).
• Recommends type-and-screen or type-and-crossmatch for women at elevated risk, and immediate availability of a massive transfusion protocol at every obstetric unit.
• Emphasises early recognition using cumulative quantitative blood loss measurement rather than visual estimation, since visual estimation systematically underestimates loss and delays transfusion.

4. WHO / FIGO 2025 Consolidated Guidelines on PPH

• Promotes the "MOTIVE" bundle of immediate actions once PPH is diagnosed (uterine massage, oxytocic drugs, tranexamic acid, IV fluids, examination/escalation).
• States blood transfusion and surgery are reserved for cases where bleeding continues despite the bundle - i.e., transfusion is a second-line, escalation-tier intervention, not first response.
• Strongly emphasises antenatal anaemia correction (daily oral iron/folate, IV iron when rapid correction is needed) as a preventive strategy, since anaemia both increases PPH risk and worsens outcomes when PPH occurs. Companion: FIGO's 2025 good practice recommendations specifically on anaemia in pregnancy to reduce PPH incidence/impact (PMID: 41031541).

5. CNGOF/SFAR Guidelines (France, 2016) and other national guidelines

Practical synthesis across guidelines

Indications for Blood Transfusion in Pregnancy

1. Early pregnancy / first-second trimester

• Ruptured ectopic pregnancy - acute intra-abdominal haemorrhage.
• Incomplete or septic abortion / miscarriage with significant blood loss.
• Molar pregnancy with haemorrhage.

2. Antenatal (third trimester)

• Severe iron-deficiency or nutritional anaemia not correctable in time with oral/IV iron - transfusion considered when Hb is severely low (classically <7 g/dl, or <10 g/dl with symptoms/near term) - Park's Textbook of Preventive and Social Medicine.
• Antepartum haemorrhage: placenta praevia, placental abruption, vasa praevia.
• Haemoglobinopathies: sickle cell disease (prophylactic or top-up transfusion to prevent crises) and thalassaemia major/intermedia, where patients may become transfusion-dependent due to hypersplenism (Bailey and Love's Short Practice of Surgery, 28th ed.).
• Placenta accreta spectrum disorders (especially in twin pregnancies), where massive haemorrhage at delivery is anticipated and blood is arranged in advance.

3. Intrapartum / peripartum - Obstetric Haemorrhage (leading indication overall)

• Postpartum haemorrhage (PPH) - uterine atony, retained tissue, genital tract trauma, coagulopathy (the "4 Ts").
• Uterine rupture.
• Placenta accreta/increta/percreta at caesarean section.
• Malaria-related severe anaemia in endemic settings.

4. Postpartum

• Correction of symptomatic anaemia from delivery blood loss (guided by clinical signs, not Hb number alone).
• Transfusion policy after severe PPH has specifically been studied in trials to define restrictive vs liberal thresholds.

Governing guidelines

• RCOG Green-top Guideline No. 47 (Blood Transfusions in Obstetrics) - group/antibody screen at booking and 28 weeks; high-risk women advised to deliver where transfusion facilities exist.
• RCOG Green-top Guideline No. 52 (Prevention and Management of PPH) - defines minor (500-1000 ml) vs major (>1000 ml) PPH and recommends unit-level massive haemorrhage protocols.
• ACOG Practice Bulletin No. 183 (Postpartum Hemorrhage) - defines PPH as cumulative loss ≥1000 ml or loss with hypovolemic signs; stresses quantitative (not visual) blood loss measurement to avoid delayed transfusion.
• WHO/FIGO 2025 consolidated PPH guidelines - transfusion and surgery positioned as escalation-tier interventions after the first-line "MOTIVE" bundle (uterotonics, tranexamic acid, fluids) fails to control bleeding; strong emphasis on antenatal anaemia correction (oral iron/folate, IV iron when rapid correction needed) as prevention.

General principle across all sources